4489 |
Anticoagulation vs. Antiplatelet After TAVR: ADAPT-TAVR Trial |
Duk-Woo Park |
Apr. 20. 23 |
4488 |
10-Year Extended Follow-up of BEST Trial |
Jung-Min Ahn |
Apr. 20. 23 |
4487 |
Routine Functional Testing or Standard Care in High-Risk Patients after PCI |
Do-Yoon Kang |
Apr. 20. 23 |
4486 |
Moderate-intensity Statin + Ezetimibe versus High-intensity Statin Monotherapy in ASCVD: RACING Trial |
Myeong-Ki Hong |
Apr. 20. 23 |
4485 |
Intravascular Imaging–Guided or Angiography-Guided Complex PCI: RENOVATE-COMPLEX-PCI |
Joo-Yong Hahn |
Apr. 20. 23 |
4484 |
FFR vs. IVUS to Guide PCI |
Bon-Kwon Koo |
Apr. 20. 23 |
4483 |
Valvular and Perivalvular Thrombosis After TAVR: ADAPT-TAVR Cardiac CT Substudy |
Yeonwoo Choi |
Apr. 20. 23 |
4482 |
Early Percutaneous Mitral Commissurotomy or Conventional Management for Asymptomatic Mitral Stenosis: A Randomised Clinical Trial |
Duk-Hyun Kang |
Apr. 20. 23 |
4481 |
Prognostic Role of Routine Stress Testing in Diabetic Patients After PCI: Key Analysis from POST-PCI |
Hoyun Kim |
Apr. 20. 23 |
4480 |
Effect of OMT on Long-Term (10-Yr) Outcomes After Myocardial Revascularization |
Jinsun Park |
Apr. 20. 23 |